Theriva Biologics Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Theriva Biologics stock has a consensus rating of "Buy" and an average price target of $2.50. The average 1-year stock price forecast is 780.90% higher than the current stock price, while the lowest is $1.00 (+252.36%) and the highest is $4.00 (+1,309.44%).

Price Target: $2.50 (+780.90%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.00	$2.50	$2.50	$4.00
Change	+252.36%	+780.90%	+780.90%	+1309.4%

Analyst Ratings

The average analyst rating for Theriva Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	May '25	Aug '25	Nov '25	Feb '26	Mar '26	May '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	1	1
Hold	1	1	1	1	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Buy Reiterates $1	Buy	Reiterates	$1	+252.36%	May 7, 2026
James Molloy Alliance Global Partners	Alliance Global Partners	Buy Reiterates $4	Buy	Reiterates	$4	+1,309.44%	May 6, 2026

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.21

from -2.08

EPS Next Year

-0.21

from -0.21

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-47.57	-32.66	-28.48	-19.03	-2.08	-0.21	-0.21
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.21	-0.21
Avg	-0.21	-0.21
Low	-0.22	-0.22

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.